10-Q quarterly report · filed Oct 21, 2026

Elevance Health (ELV) Q3 2026 10-Q Quarterly Report

Short answer

Elevance Health (ELV) filed its Q3 2026 10-Q quarterly report on Oct 21, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $51.4B (up 1.4% year over year) with net income of $1.4B.

Q3 2026 key financials · XBRL

Revenue
$51.4B
+1.4% YoY · +1.9% QoQ
Net income
$1.4B
+14.8% YoY · −6.7% QoQ
Operating margin
2.5%
EPS (diluted)
$6.28
+17.6% YoY · −6.7% QoQ

Source: XBRL data from the Elevance Health (ELV) Q3 2026 10-Q on SEC EDGAR. USD.

Elevance Health Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly operating revenue $50,440, up 0.7% from $50,087 YoY
  • Operating margin 2.5% vs 2.6% YoY, benefit expense ratio 90.6% vs 91.3%
  • Best segment: CarelonRx revenue $11,599, up 5.5%, operating margin 5.3% vs 5.1%
  • Worst segment: Health Benefits operating gain $3,489, down 20.3%, margin 1.0% vs 1.4%
  • Operating cash flow $7,512 vs $4,206; investments $2,303, buybacks $1,688, dividends $1,122, debt repayments $900 year-to-date
  • Near-term headwinds: elevated Medicaid medical costs, lower membership, expired APTCs, regulatory changes and Medicare Advantage Star Ratings declining to 49% alts

Risk Factors

  • No risk factors section provided, limiting comparison with the 2025 Form 10-K
  • Seasonal healthcare demand and competitive conditions may distort interim results versus full-year performance
  • Foreign-currency translation exposure from subsidiaries operating outside the United States
  • Medical membership concentration: approximately 44.9 million members as of September 30, 2026

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Elevance Health quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.